Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Buy, Sell - Buy enter button by Ardasavasciogullari via iStock
This Biotech Stock Insider is Buying Shares, Should You? Barchart - Thu Oct 17, 6:30AM CDT

This Nuvation Bio board member and longtime biotech industry insider carried out his first purchase since his appointment in January.

$NASX : 18,972.42 (+0.03%)
TNDM : 30.74 (+1.96%)
$SPX : 5,948.71 (+0.53%)
NUVB : 2.70 (+4.65%)
VRTX : 450.37 (-0.19%)
SNY : 47.98 (+0.42%)
Dollars and Wallets - Pile of money with hands by Sergey Nazarov via iStock
2 'Strong Buy'-Rated Penny Stocks That Could Skyrocket 192% to 205% in 2025 Barchart - Thu Oct 3, 10:22AM CDT

A promising product portfolio could boost this biotech company’s financials in the near future.

STLA : 12.85 (unch)
ACHR : 5.78 (+14.23%)
$SPX : 5,948.71 (+0.53%)
NUVB : 2.70 (+4.65%)
Wall Street - shutterstock_156562427
3 Standout Stocks Under $10 With 86% Upside Potential or More Barchart - Wed Jul 24, 7:59AM CDT

As the chances for a September rate cut grow even stronger, these three penny stocks can emerge as substantial wealth creators.

AMZN : 198.38 (-2.22%)
AAPL : 228.52 (-0.21%)
NVDA : 146.67 (+0.53%)
OPAL : 3.70 (+0.82%)
OCUL : 8.52 (-2.96%)
NUVB : 2.70 (+4.65%)
Biotech Sector Advances in Pancreatic Cancer Research BayStreet.ca - Thu Mar 14, 8:42AM CDT

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 29.73 (+0.34%)
ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
NVS : 103.85 (+0.74%)
IBRX : 5.04 (+3.28%)
ACRS : 4.32 (+9.09%)
NUVB : 2.70 (+4.65%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency FinancialNewsMedia - Thu Mar 14, 7:45AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 1.9200 (-2.54%)
ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
NVS : 103.85 (+0.74%)
IBRX : 5.04 (+3.28%)
ACRS : 4.32 (+9.09%)
NUVB : 2.70 (+4.65%)
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update Business Wire - Thu May 4, 2023

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 2.70 (+4.65%)
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Business Wire - Wed Mar 15, 2023

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial...

NUVB : 2.70 (+4.65%)
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868 Business Wire - Mon Dec 19, 2022

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed...

NUVB : 2.70 (+4.65%)
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update Business Wire - Thu Nov 3, 2022

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 2.70 (+4.65%)
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update Business Wire - Thu Aug 4, 2022

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 2.70 (+4.65%)

Barchart Exclusives

Recent Corn Rally Artificially Propped Up – What’s Next? Barchart - 11 minutes ago
Corn prices appeared to have finally found a bottom from the summer sell-off. Speculators were short the market in record numbers until late August, when they began buying back contracts, convincing some that the harvest seasonal low may be in. Then, exports increased in the last few weeks, and prices rallied more. While the bearish fundamentals of 1.9 billion carry-out and the massive amount of unpriced corn still linger, there isn’t much hope for a significant price rally yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot